Brokerages Set Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Price Target at $11.67

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) has received a consensus rating of “Buy” from the seven analysts that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, four have given a buy rating and two have assigned a strong buy rating to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $11.6667.

EPRX has been the subject of several research reports. Leede Financial raised Eupraxia Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, October 29th. Lifesci Capital upgraded Eupraxia Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, December 11th. Wall Street Zen raised Eupraxia Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, December 13th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research note on Wednesday, October 8th.

Eupraxia Pharmaceuticals Trading Up 2.7%

Shares of EPRX opened at $7.19 on Friday. Eupraxia Pharmaceuticals has a twelve month low of $2.68 and a twelve month high of $7.37. The firm has a market capitalization of $258.55 million, a P/E ratio of -8.26 and a beta of 1.38. The firm’s 50-day moving average is $6.05 and its two-hundred day moving average is $5.57.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last announced its quarterly earnings results on Tuesday, November 4th. The company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.04. Analysts predict that Eupraxia Pharmaceuticals will post -0.67 EPS for the current year.

Institutional Trading of Eupraxia Pharmaceuticals

Several large investors have recently modified their holdings of the business. Quadrature Capital Ltd acquired a new position in shares of Eupraxia Pharmaceuticals during the 2nd quarter worth approximately $61,000. TCI Wealth Advisors Inc. acquired a new stake in Eupraxia Pharmaceuticals during the 3rd quarter valued at $65,000. Integrated Wealth Concepts LLC purchased a new position in Eupraxia Pharmaceuticals during the third quarter worth $71,000. Bank of America Corp DE raised its holdings in shares of Eupraxia Pharmaceuticals by 402.4% in the second quarter. Bank of America Corp DE now owns 12,559 shares of the company’s stock worth $72,000 after acquiring an additional 10,059 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its position in shares of Eupraxia Pharmaceuticals by 593.2% in the second quarter. JPMorgan Chase & Co. now owns 18,717 shares of the company’s stock valued at $108,000 after acquiring an additional 16,017 shares in the last quarter.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.